Illumina Ventures

Attovia Therapeutics is a biotherapeutics pipeline developer focused on immune-mediated illness and oncology. The company uses the nanobody platform to create tiny format binders with low picomolar affinity, increased selectivity, quicker internalization, and rapid tissue penetration, thereby assisting cancer patients' treatment.

SyntaxBio develops CRISPR/Cas9-based, genetic programming platform that converts cells into biological computers using DNA-based instructions that read like lines of code. SyntaxBio's platform can program cells without the need for consistent external intervention.

Attovia Therapeutics is a biotherapeutics pipeline developer focused on immune-mediated illness and oncology. The company uses the nanobody platform to create tiny format binders with low picomolar affinity, increased selectivity, quicker internalization, and rapid tissue penetration, thereby assisting cancer patients' treatment.

Iambic Therapeutics focuses on accelerating molecular discovery through its innovative quantum molecular simulation engine. By integrating artificial intelligence and automated synthetic development, the company aims to enhance the design of small-molecule therapeutics. This technology significantly improves the accuracy of molecular predictions, providing valuable insights for therapeutic discovery. Iambic Therapeutics is committed to transforming the drug development process, enabling physicians to access more precise molecular data and ultimately improving treatment outcomes.

Stilla Technologies is a Paris-based biotechnology company that accelerates genetic test development by delivering the Naica System, a digital PCR (dPCR) platform. Built on microfluidic innovations, the Naica System aims to broaden dPCR from a specialized tool to a widely accessible technology across life sciences, including research, therapeutics, and omics. The platform supports multiple chemistries and multiplexing to enable high-resolution genetic analysis and actionable insights across applications such as cancer and liquid biopsy, cell and gene therapies, infectious disease detection, and food and environmental testing. Founded in 2013 and headquartered in Villejuif, France, the company serves customers globally and focuses on simplifying image analysis and data exploration to help researchers derive clear results from complex genomic data.

Tagomics is a company focused on enhancing disease diagnosis through advanced multitopic profiling and epigenetic-based chemical modifications. By leveraging epigenetics, Tagomics aims to provide a deeper understanding of biological processes by adding an additional layer of information to the genetic code. This approach allows for the discovery of dynamic and sensitive biomarkers that can reflect the influence of lifestyle, environmental factors, and disease progression. The company's innovations are particularly aimed at early detection of colorectal and other common cancers, promoting cost-effective and efficient epigenetic biomarker discovery. Through its work, Tagomics is transforming the landscape of disease diagnosis and patient care.

Actym Therapeutics is a biotechnology company based in Berkeley, California. Founded in 2017, the company specializes in the discovery and development of novel immuno-oncology therapies to treat cancer. Actym's proprietary platform, STACT, uses attenuated bacteria to deliver multiplexed immunomodulatory payloads directly to tumor-resident immune cells, targeting intractable pathways with minimal systemic toxicities.

Precede Biosciences is breaking down the barriers to precision medicine by redefining what can be gleaned from a simple blood draw. Precede aims to increase drug development success rates and to contribute to a future in which every patient can receive a speedy, minimally invasive diagnosis and therapy tailored to the biology of their condition.

Iambic Therapeutics focuses on accelerating molecular discovery through its innovative quantum molecular simulation engine. By integrating artificial intelligence and automated synthetic development, the company aims to enhance the design of small-molecule therapeutics. This technology significantly improves the accuracy of molecular predictions, providing valuable insights for therapeutic discovery. Iambic Therapeutics is committed to transforming the drug development process, enabling physicians to access more precise molecular data and ultimately improving treatment outcomes.

Broken String Biosciences is focused on developing a novel sequencing platform aimed at assessing genome stability to enhance the safety and efficacy of cell and gene therapies. By integrating advanced sequencing techniques with bioinformatics analysis and artificial intelligence, the company provides healthcare professionals with a comprehensive, data-driven approach to medicine. This innovative platform is designed to facilitate the development of the next generation of therapies, ensuring they are safer by design and capable of addressing various medical challenges. Through its efforts, Broken String Biosciences aims to unlock new possibilities in the realm of advanced therapeutic solutions.

Lightcast Discovery Limited, founded in 2019 and based in Cambridge, United Kingdom, specializes in drug discovery through advanced microfluidic technology. The company focuses on developing new therapies and innovative products by leveraging its unique platform, which allows for the precise and flexible control of thousands of droplets. This capability enables the combination of various cells, reporters, and reagents to conduct complex workflows without manual cell manipulation. By collaborating with major pharmaceutical companies and leading academic institutions, Lightcast Discovery seeks to enhance complex cell analysis and facilitate the discovery of new clinical approaches.

Attovia Therapeutics is a biotherapeutics pipeline developer focused on immune-mediated illness and oncology. The company uses the nanobody platform to create tiny format binders with low picomolar affinity, increased selectivity, quicker internalization, and rapid tissue penetration, thereby assisting cancer patients' treatment.

Pluton Biosciences is a bioscience research company that specializes in the testing and discovery of microbes for the development of various products, primarily focusing on biopesticides and pharmaceuticals. Utilizing an innovative platform, the company mines and clones microbes to generate a range of beneficial products aimed at enhancing biopesticides, crop protection, human health, and bioremediation. By harnessing the potential of bacteria, fungi, and viruses, Pluton Biosciences enables medical researchers and agricultural professionals to explore sustainable and all-natural solutions for various applications, contributing to advancements in both environmental and health-related sectors.

Pattern Bioscience, Inc., known as Klaris Diagnostics, Inc., is a clinical diagnostics company based in Austin, Texas, that focuses on addressing antibiotic resistance. Founded in 2016, the company has developed a next-generation clinical microbiology platform utilizing its patented phenotypic single-cell technology. This innovative approach allows for rapid pathogen identification and antibiotic susceptibility testing without the lengthy culture processes typical of traditional methods. Pattern Bioscience's Digital Culture technology employs artificial intelligence and single-cell analysis, producing comprehensive and reliable diagnostic results significantly faster than the current standard of care. By integrating functional endpoints that account for various resistance mechanisms, the company aims to enhance the accuracy and efficiency of diagnoses in the fight against antibiotic-resistant infections.

Protillion Biosciences is a biotechnology company focused on transforming therapeutic antibody and drug discovery through its innovative protein engineering platform. This high-throughput platform is designed to streamline and enhance traditional methods of designing and developing protein-based drugs. By utilizing advanced techniques, Protillion aims to accelerate the research and development process for biologics, thereby enabling healthcare professionals to discover and bring new protein therapeutics to market more efficiently. The company's commitment to developing disruptive technology positions it as a key player in the evolving landscape of drug discovery and development.

SonoThera is a biotechnology company focused on developing innovative genetic therapies using ultrasound technology. The company's mission is to create non-viral genetic medicines that address the root causes of human diseases. SonoThera specializes in ultrasound-guided nonviral gene therapy, aiming to provide effective treatments for conditions that currently have suboptimal or no available treatments. By leveraging this approach, SonoThera seeks to enhance the health and quality of life for millions of people worldwide.

LetsGetChecked is an at-home health testing platform that connects users with regulated laboratories for various tests, including general wellness, sexual health, women's health, men's health, and COVID-19. Headquartered in New York, the company operates nationwide in the U.S., Canada, and Europe.

Sherlock Biosciences, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative molecular diagnostic solutions. The company utilizes advanced engineering biology tools, such as CRISPR and synthetic biology, to create diagnostic platforms capable of delivering accurate and rapid results. Its notable technologies include SHERLOCK, a method for detecting and quantifying specific genetic sequences, and INSPECTR, which is designed for versatile, easy-to-use diagnostics. Sherlock Biosciences aims to serve various applications, including precision oncology, infectious disease identification, food safety, at-home testing, and general disease detection. Founded in 2018, the company is committed to providing affordable diagnostics suitable for diverse settings, including those with low-resource environments.

Kallyope Inc. is a biotechnology company based in New York City that focuses on understanding the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Established in 2014, Kallyope employs advanced technologies, including sequencing, computational biology, neural imaging, and human genetics, to explore gut-brain biology. The company aims to address significant unmet medical needs, such as diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies, by creating effective and user-friendly oral agents. Kallyope's team consists of experienced scientists from leading institutions, working alongside a skilled team with a strong track record in drug discovery and development. Through its research, Kallyope seeks to deliver transformative solutions that improve overall health outcomes.

Stilla Technologies is a Paris-based biotechnology company that accelerates genetic test development by delivering the Naica System, a digital PCR (dPCR) platform. Built on microfluidic innovations, the Naica System aims to broaden dPCR from a specialized tool to a widely accessible technology across life sciences, including research, therapeutics, and omics. The platform supports multiple chemistries and multiplexing to enable high-resolution genetic analysis and actionable insights across applications such as cancer and liquid biopsy, cell and gene therapies, infectious disease detection, and food and environmental testing. Founded in 2013 and headquartered in Villejuif, France, the company serves customers globally and focuses on simplifying image analysis and data exploration to help researchers derive clear results from complex genomic data.

DNA Script is a Paris-based company that develops synthetic biology tools focused on DNA synthesis. It employs enzymatic processes to produce synthetic nucleic acids, including oligonucleotides, enabling genomics and molecular biology applications. Founded in 2014, it introduced the SYNTAX benchtop DNA printer to provide labs with greater workflow control and faster access to results. By producing DNA through natural enzymes, the company aims to accelerate research and the development of new therapeutics.

RedShift BioAnalytics, Inc. is a company that develops and provides analytical instrumentation aimed at the research, development, and manufacture of protein therapeutic drugs and biopharmaceutical products. The company's flagship product, ProLaser, is a benchtop instrument designed for the rapid characterization of proteins throughout the drug development process, including lead candidate selection, preformulation, formulation development, process optimization, stability assessment, routine analytics, and quality control. RedShift BioAnalytics also offers a Microfluidic Modulation Spectroscopy (MMS) platform, developed specifically for protein scientists to measure previously undetectable changes in protein structural attributes critical to drug efficacy and quality. Founded in 2005 and headquartered in Burlington, Massachusetts, the company serves the life sciences and biopharmaceutical markets, focusing on enhancing decision-making in biopharmaceutical development from discovery to market.

Walking Fish Therapeutics is focused on developing innovative cell-based therapeutics aimed at treating serious diseases, particularly in the fields of oncology and regenerative medicine. The company leverages the unique capabilities of B cells to activate the immune system, thereby creating treatments for cancer and other conditions. Additionally, these B cell factories can function as in vivo protein producers, generating replacement proteins for deficiency diseases and engineered antibodies. By harnessing locally acting proteins, Walking Fish Therapeutics seeks to enhance therapeutic outcomes and provide targeted solutions for patients suffering from various ailments.

Alamar Biosciences, founded in 2018 and headquartered in Fremont, California, specializes in developing advanced technologies for the early detection and treatment of cancer and other diseases. The company focuses on a precision proteomics platform that facilitates protein analysis and the creation of antibody technologies. This platform is designed to enhance the diagnosis of diseases, particularly cancer, while also supporting the discovery of new biomarkers. By enabling healthcare providers to detect diseases at an early stage, Alamar Biosciences aims to improve patient outcomes through timely interventions and potential cures.

Genome Medical operates a platform that connects individuals and healthcare providers with genetic specialists. It offers virtual genetic care services, including clinical consultations for various health areas like cancer, cardiology, and reproductive health. The company uses its Genome Care Delivery technology to facilitate efficient genetic assessments and personalized treatment plans.

NanoCellect Biomedical, Inc., established in 2009 and headquartered in San Diego, California, specializes in developing innovative flow cytometry and cell sorting solutions for life science researchers. The company's flagship product, the WOLF Cell Sorter, employs a unique closed fluid-path microfluidic cartridge to facilitate efficient cell sorting while mitigating biohazard risks and shear stress issues common in traditional methods. Their portfolio of affordable, compact, and user-friendly instruments and consumables caters to various applications such as drug discovery, single-cell omics, cloning, antibody discovery, and basic research, empowering biomedical scientists with simplified cellular analysis and sorting capabilities.

LetsGetChecked is an at-home health testing platform that connects users with regulated laboratories for various tests, including general wellness, sexual health, women's health, men's health, and COVID-19. Headquartered in New York, the company operates nationwide in the U.S., Canada, and Europe.

NanoCellect Biomedical, Inc., established in 2009 and headquartered in San Diego, California, specializes in developing innovative flow cytometry and cell sorting solutions for life science researchers. The company's flagship product, the WOLF Cell Sorter, employs a unique closed fluid-path microfluidic cartridge to facilitate efficient cell sorting while mitigating biohazard risks and shear stress issues common in traditional methods. Their portfolio of affordable, compact, and user-friendly instruments and consumables caters to various applications such as drug discovery, single-cell omics, cloning, antibody discovery, and basic research, empowering biomedical scientists with simplified cellular analysis and sorting capabilities.

Delfi Diagnostics, Inc. is a biotechnology company based in Baltimore, Maryland, focused on the early detection of cancer through innovative blood tests. Founded in 2018, the company employs artificial intelligence and genome sequencing to identify unique patterns of DNA fragmentation in the blood, enabling the detection of previously unrecognized cancer-associated cell-free DNA fragments. By utilizing machine learning, Delfi Diagnostics aims to develop high-precision, non-invasive blood tests that allow healthcare professionals to detect cancer at its most curable stage, thereby facilitating timely and effective treatment options for patients.

Rebus Biosystems, Inc. is a life science technology company based in Santa Clara, California, specializing in spatial omics research tools. Founded in 2006 and previously known as Optical Biosystems, the company has developed the Rebus Esper, an automated spatial omics platform that delivers quantitative data at single molecule and single-cell resolution. This innovative system integrates advanced imaging, on-system chemistry, and user-friendly software to provide researchers with an end-to-end solution that minimizes hands-on time. Rebus Biosystems also offers comprehensive assay kits designed to enhance the resolution, scale, and speed of their platform, enabling pharmaceutical and research organizations to analyze gene expression profiles across large tissue sections efficiently and accurately.

DNA Script is a Paris-based company that develops synthetic biology tools focused on DNA synthesis. It employs enzymatic processes to produce synthetic nucleic acids, including oligonucleotides, enabling genomics and molecular biology applications. Founded in 2014, it introduced the SYNTAX benchtop DNA printer to provide labs with greater workflow control and faster access to results. By producing DNA through natural enzymes, the company aims to accelerate research and the development of new therapeutics.

Encoded Therapeutics is a biotechnology company focused on precision gene therapies to treat a broad range of severe genetic disorders. It develops therapies and a platform that identifies human genome sequences that regulate gene expression using screening and computational approaches. The company's pipeline targets conditions across multiple pathways, including neurocircuitry, liver and metabolic disorders, neurodegeneration, and cardiovascular disease, aiming to help medical practitioners treat patients and improve outcomes. Based in South San Francisco, California, Encoded Therapeutics was founded in 2014 and was previously known as Encoded Genomics.

Pattern Bioscience, Inc., known as Klaris Diagnostics, Inc., is a clinical diagnostics company based in Austin, Texas, that focuses on addressing antibiotic resistance. Founded in 2016, the company has developed a next-generation clinical microbiology platform utilizing its patented phenotypic single-cell technology. This innovative approach allows for rapid pathogen identification and antibiotic susceptibility testing without the lengthy culture processes typical of traditional methods. Pattern Bioscience's Digital Culture technology employs artificial intelligence and single-cell analysis, producing comprehensive and reliable diagnostic results significantly faster than the current standard of care. By integrating functional endpoints that account for various resistance mechanisms, the company aims to enhance the accuracy and efficiency of diagnoses in the fight against antibiotic-resistant infections.

Genome Medical operates a platform that connects individuals and healthcare providers with genetic specialists. It offers virtual genetic care services, including clinical consultations for various health areas like cancer, cardiology, and reproductive health. The company uses its Genome Care Delivery technology to facilitate efficient genetic assessments and personalized treatment plans.

SQZ Biotech is a clinical-stage biotechnology company focused on developing innovative cell therapies for cancer, infectious diseases, and other serious health conditions. Utilizing its proprietary CellSqueeze technology, the company can deliver a variety of materials into diverse patient cell types, enabling the engineering of therapies that address a wide range of clinical challenges. SQZ Biotech aims to create well-tolerated and effective cell therapies that enhance patient experiences compared to traditional approaches. With its commitment to internal research and strategic partnerships, SQZ is working to advance a new generation of cell therapies through both immune activation and immune suppression methods, showcasing its potential to transform treatment options for patients.

LetsGetChecked is an at-home health testing platform that connects users with regulated laboratories for various tests, including general wellness, sexual health, women's health, men's health, and COVID-19. Headquartered in New York, the company operates nationwide in the U.S., Canada, and Europe.

Actym Therapeutics is a biotechnology company based in Berkeley, California. Founded in 2017, the company specializes in the discovery and development of novel immuno-oncology therapies to treat cancer. Actym's proprietary platform, STACT, uses attenuated bacteria to deliver multiplexed immunomodulatory payloads directly to tumor-resident immune cells, targeting intractable pathways with minimal systemic toxicities.

Kallyope Inc. is a biotechnology company based in New York City that focuses on understanding the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Established in 2014, Kallyope employs advanced technologies, including sequencing, computational biology, neural imaging, and human genetics, to explore gut-brain biology. The company aims to address significant unmet medical needs, such as diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies, by creating effective and user-friendly oral agents. Kallyope's team consists of experienced scientists from leading institutions, working alongside a skilled team with a strong track record in drug discovery and development. Through its research, Kallyope seeks to deliver transformative solutions that improve overall health outcomes.

Stilla Technologies is a Paris-based biotechnology company that accelerates genetic test development by delivering the Naica System, a digital PCR (dPCR) platform. Built on microfluidic innovations, the Naica System aims to broaden dPCR from a specialized tool to a widely accessible technology across life sciences, including research, therapeutics, and omics. The platform supports multiple chemistries and multiplexing to enable high-resolution genetic analysis and actionable insights across applications such as cancer and liquid biopsy, cell and gene therapies, infectious disease detection, and food and environmental testing. Founded in 2013 and headquartered in Villejuif, France, the company serves customers globally and focuses on simplifying image analysis and data exploration to help researchers derive clear results from complex genomic data.

Fluent BioSciences is a life science technology company focused on single-cell molecular analysis, eliminating the need for complex microfluidic instrumentation. The company’s proprietary platform, Pre-Templated Instant Partitions (PIPseqTM), facilitates the instantaneous self-assembly of individual cells or molecules into millions of uniform partitions. This innovative approach allows for sensitive and unbiased preparation of proteins and nucleic acids, enhancing sequencing applications. By making single-cell and molecular analysis more accessible, Fluent BioSciences enables a broader range of researchers in biotechnology, pharmaceuticals, and academic institutions to conduct advanced analyses, thereby expanding market opportunities within the life sciences field.

Ribometrix is a biotechnology company that develops platform therapeutics to discover and advance small molecule drugs that target functional three-dimensional RNA structures to treat human diseases. Founded in 2014 and based in Durham, North Carolina, it focuses on leveraging RNA structure analysis and proprietary tools, along with artificial intelligence, to identify compounds that modulate RNA biology and reduce disease-associated protein production.

Delfi Diagnostics, Inc. is a biotechnology company based in Baltimore, Maryland, focused on the early detection of cancer through innovative blood tests. Founded in 2018, the company employs artificial intelligence and genome sequencing to identify unique patterns of DNA fragmentation in the blood, enabling the detection of previously unrecognized cancer-associated cell-free DNA fragments. By utilizing machine learning, Delfi Diagnostics aims to develop high-precision, non-invasive blood tests that allow healthcare professionals to detect cancer at its most curable stage, thereby facilitating timely and effective treatment options for patients.

Cradle Genomics, Inc. is a biotechnology company focused on advancing non-invasive prenatal testing (NIPT) through comprehensive fetal genetic analysis and pregnancy health screening solutions. Founded in 2018 and headquartered in San Diego, California, with research and development operations in Detroit, Michigan, the company aims to enhance the knowledge available to expectant parents. Cradle Genomics specializes in analyzing fetal cells collected during the first trimester, allowing for rapid and safe testing that poses no risk to the mother or developing fetus. By providing critical insights early in pregnancy, Cradle Genomics empowers women to make informed health decisions.

Encoded Therapeutics is a biotechnology company focused on precision gene therapies to treat a broad range of severe genetic disorders. It develops therapies and a platform that identifies human genome sequences that regulate gene expression using screening and computational approaches. The company's pipeline targets conditions across multiple pathways, including neurocircuitry, liver and metabolic disorders, neurodegeneration, and cardiovascular disease, aiming to help medical practitioners treat patients and improve outcomes. Based in South San Francisco, California, Encoded Therapeutics was founded in 2014 and was previously known as Encoded Genomics.

DNA Script is a Paris-based company that develops synthetic biology tools focused on DNA synthesis. It employs enzymatic processes to produce synthetic nucleic acids, including oligonucleotides, enabling genomics and molecular biology applications. Founded in 2014, it introduced the SYNTAX benchtop DNA printer to provide labs with greater workflow control and faster access to results. By producing DNA through natural enzymes, the company aims to accelerate research and the development of new therapeutics.

LunaDNA is a community-owned genomic and medical research platform founded by the creators of a leading DNA sequencing company. It facilitates the sharing of health and DNA data, allowing individuals to contribute their personal information for medical research while maintaining ownership of their data. By incentivizing participation, LunaDNA addresses the challenge of data silos that have emerged as personal DNA sequencing has gained popularity. Participants are rewarded with shares in the database, granting them a stake in the profits generated from medical research. These profits are returned to the community as dividends when researchers pay for access to the data. LunaDNA empowers individuals to support health research while ensuring that their contributions benefit the broader community and drive medical discoveries.

LunaPBC, Inc. is a Public Benefit Corporation based in San Diego, California, focused on developing a community-owned platform for health and DNA research. The company's primary offering is LunaDNA, a genomic and medical research knowledge database that enables individuals to share their health and DNA data for research purposes. This platform facilitates collaborations with pharmaceutical companies, insurance providers, and healthcare IT organizations to drive advancements in medical discoveries. By allowing members to contribute their health data, LunaPBC not only supports vital health research projects but also ensures that participants can share in the financial benefits arising from medical breakthroughs, fostering a sense of community ownership and engagement in the research process.

Kallyope Inc. is a biotechnology company based in New York City that focuses on understanding the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Established in 2014, Kallyope employs advanced technologies, including sequencing, computational biology, neural imaging, and human genetics, to explore gut-brain biology. The company aims to address significant unmet medical needs, such as diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies, by creating effective and user-friendly oral agents. Kallyope's team consists of experienced scientists from leading institutions, working alongside a skilled team with a strong track record in drug discovery and development. Through its research, Kallyope seeks to deliver transformative solutions that improve overall health outcomes.

Stilla Technologies is a Paris-based biotechnology company that accelerates genetic test development by delivering the Naica System, a digital PCR (dPCR) platform. Built on microfluidic innovations, the Naica System aims to broaden dPCR from a specialized tool to a widely accessible technology across life sciences, including research, therapeutics, and omics. The platform supports multiple chemistries and multiplexing to enable high-resolution genetic analysis and actionable insights across applications such as cancer and liquid biopsy, cell and gene therapies, infectious disease detection, and food and environmental testing. Founded in 2013 and headquartered in Villejuif, France, the company serves customers globally and focuses on simplifying image analysis and data exploration to help researchers derive clear results from complex genomic data.

Ribometrix is a biotechnology company that develops platform therapeutics to discover and advance small molecule drugs that target functional three-dimensional RNA structures to treat human diseases. Founded in 2014 and based in Durham, North Carolina, it focuses on leveraging RNA structure analysis and proprietary tools, along with artificial intelligence, to identify compounds that modulate RNA biology and reduce disease-associated protein production.

SQZ Biotech is a clinical-stage biotechnology company focused on developing innovative cell therapies for cancer, infectious diseases, and other serious health conditions. Utilizing its proprietary CellSqueeze technology, the company can deliver a variety of materials into diverse patient cell types, enabling the engineering of therapies that address a wide range of clinical challenges. SQZ Biotech aims to create well-tolerated and effective cell therapies that enhance patient experiences compared to traditional approaches. With its commitment to internal research and strategic partnerships, SQZ is working to advance a new generation of cell therapies through both immune activation and immune suppression methods, showcasing its potential to transform treatment options for patients.

LunaDNA is a community-owned genomic and medical research platform founded by the creators of a leading DNA sequencing company. It facilitates the sharing of health and DNA data, allowing individuals to contribute their personal information for medical research while maintaining ownership of their data. By incentivizing participation, LunaDNA addresses the challenge of data silos that have emerged as personal DNA sequencing has gained popularity. Participants are rewarded with shares in the database, granting them a stake in the profits generated from medical research. These profits are returned to the community as dividends when researchers pay for access to the data. LunaDNA empowers individuals to support health research while ensuring that their contributions benefit the broader community and drive medical discoveries.

Cernostics, Inc. is a diagnostics company based in Pittsburgh, Pennsylvania, specializing in cancer diagnostics and prognostics. Founded in 2008, the company employs a tissue systems biology approach to anatomic pathology, focusing on comprehensive evaluations of tumors composed of various cell types. Cernostics has developed the TissueCypher Barrett’s esophagus assay, which utilizes whole slide digital imaging technology to assess risk in Barrett’s esophagus patients, thereby aiding gastroenterologists in treatment decisions. The company’s innovative platform features advanced capabilities such as multi-channel fluorescence imaging, image reading, image segmentation, and biomarker expression analysis. Cernostics aims to provide insights into disease pathophysiology, facilitate biomarker discovery and validation, and support clinical trials, ultimately enhancing patient outcomes and reducing healthcare costs. The company also collaborates strategically with Deciphex Limited to further advance its technological initiatives.

Kallyope Inc. is a biotechnology company based in New York City that focuses on understanding the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Established in 2014, Kallyope employs advanced technologies, including sequencing, computational biology, neural imaging, and human genetics, to explore gut-brain biology. The company aims to address significant unmet medical needs, such as diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies, by creating effective and user-friendly oral agents. Kallyope's team consists of experienced scientists from leading institutions, working alongside a skilled team with a strong track record in drug discovery and development. Through its research, Kallyope seeks to deliver transformative solutions that improve overall health outcomes.

NanoCellect Biomedical, Inc., established in 2009 and headquartered in San Diego, California, specializes in developing innovative flow cytometry and cell sorting solutions for life science researchers. The company's flagship product, the WOLF Cell Sorter, employs a unique closed fluid-path microfluidic cartridge to facilitate efficient cell sorting while mitigating biohazard risks and shear stress issues common in traditional methods. Their portfolio of affordable, compact, and user-friendly instruments and consumables caters to various applications such as drug discovery, single-cell omics, cloning, antibody discovery, and basic research, empowering biomedical scientists with simplified cellular analysis and sorting capabilities.

Genome Medical operates a platform that connects individuals and healthcare providers with genetic specialists. It offers virtual genetic care services, including clinical consultations for various health areas like cancer, cardiology, and reproductive health. The company uses its Genome Care Delivery technology to facilitate efficient genetic assessments and personalized treatment plans.

LunaDNA is a community-owned genomic and medical research platform founded by the creators of a leading DNA sequencing company. It facilitates the sharing of health and DNA data, allowing individuals to contribute their personal information for medical research while maintaining ownership of their data. By incentivizing participation, LunaDNA addresses the challenge of data silos that have emerged as personal DNA sequencing has gained popularity. Participants are rewarded with shares in the database, granting them a stake in the profits generated from medical research. These profits are returned to the community as dividends when researchers pay for access to the data. LunaDNA empowers individuals to support health research while ensuring that their contributions benefit the broader community and drive medical discoveries.

NanoCellect Biomedical, Inc., established in 2009 and headquartered in San Diego, California, specializes in developing innovative flow cytometry and cell sorting solutions for life science researchers. The company's flagship product, the WOLF Cell Sorter, employs a unique closed fluid-path microfluidic cartridge to facilitate efficient cell sorting while mitigating biohazard risks and shear stress issues common in traditional methods. Their portfolio of affordable, compact, and user-friendly instruments and consumables caters to various applications such as drug discovery, single-cell omics, cloning, antibody discovery, and basic research, empowering biomedical scientists with simplified cellular analysis and sorting capabilities.

DNA Script is a Paris-based company that develops synthetic biology tools focused on DNA synthesis. It employs enzymatic processes to produce synthetic nucleic acids, including oligonucleotides, enabling genomics and molecular biology applications. Founded in 2014, it introduced the SYNTAX benchtop DNA printer to provide labs with greater workflow control and faster access to results. By producing DNA through natural enzymes, the company aims to accelerate research and the development of new therapeutics.

Serimmune Inc. is a biotechnology company based in Goleta, California, focused on developing diagnostics and therapeutics for autoimmune diseases. Founded in 2014, the company utilizes a universal serology platform that incorporates bacterial display peptide libraries, sequencing, and machine learning to analyze immune responses. Through its serum epitope repertoire analysis (SERA) technology, Serimmune can identify a diverse array of antigens that stimulate immunity, mapping specific antibodies to various diseases, including infections, allergies, autoimmune disorders, and cancers. This innovative approach allows for comprehensive profiling of antibody repertoires in a single assay, ultimately aiding medical practitioners in the diagnosis and treatment of various health conditions.

Genome Medical operates a platform that connects individuals and healthcare providers with genetic specialists. It offers virtual genetic care services, including clinical consultations for various health areas like cancer, cardiology, and reproductive health. The company uses its Genome Care Delivery technology to facilitate efficient genetic assessments and personalized treatment plans.

Founded in 2013, Human Longevity is a genomic-based health intelligence company headquartered in San Diego, California. It combines the largest database of genomic and phenotypic data with machine learning to drive discoveries and empower proactive healthcare. The company's core offerings include the HLI Health Nucleus, which uses whole-genome sequence analysis and advanced clinical imaging to deliver comprehensive personal health insights.

Twist Bioscience Corporation is a synthetic biology company that specializes in the manufacture and sale of synthetic DNA-based products. Founded in 2013 and headquartered in South San Francisco, California, the company utilizes a proprietary semiconductor-based DNA synthesis platform that writes DNA on silicon chips, allowing for the rapid and cost-effective production of high-quality synthetic DNA. Twist Bioscience's offerings include synthetic genes, tools for sample preparation, antibody libraries for drug discovery, and DNA as a medium for digital data storage. The company serves various sectors, including healthcare, agriculture, and industrial chemicals, supporting customers in their efforts to enhance lives and promote sustainability. Through its innovative platform, Twist Bioscience aims to overcome traditional inefficiencies in DNA synthesis, enabling researchers to accelerate their projects.

Desktop Genetics is an international biotechnology company to helps researchers discover and treat the root genetic causes of human disease. Desktop Genetics is a recognized leader in genome editing technology, staffed by a dedicated team of genome editing experts, bioinformaticians, and data scientists. The company's tools and technologies are used by organizations all over the world. It enables the work of their pharma, biotech, and academic customers working in drug discovery and functional genomics.

Biota Technology applies DNA sequencing and data science to the earth's subsurface to provide diagnostics for the oil and gas industry, including production profiling, reservoir connectivity, drainage volumes, and engineered completions. Its DNA data services deliver actionable insights to maximize reservoir economics and reduce environmental impact. The company's patented technology has been applied on over 500 wells by a majority of the top producers in US shale. Founded in 2012 and based in San Diego, California.

Kallyope Inc. is a biotechnology company based in New York City that focuses on understanding the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Established in 2014, Kallyope employs advanced technologies, including sequencing, computational biology, neural imaging, and human genetics, to explore gut-brain biology. The company aims to address significant unmet medical needs, such as diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies, by creating effective and user-friendly oral agents. Kallyope's team consists of experienced scientists from leading institutions, working alongside a skilled team with a strong track record in drug discovery and development. Through its research, Kallyope seeks to deliver transformative solutions that improve overall health outcomes.

23andMe, Inc. is a consumer genetics and research company headquartered in Sunnyvale, California, founded in 2006. It specializes in providing direct-to-consumer personal genome services through home-based saliva collection kits. The company offers a range of services, including Health + Ancestry, which provides insights into ancestry, traits, and health, and Ancestry + Traits, which details ancestry breakdown and various trait reports. 23andMe aims to help individuals understand their genetic makeup, enabling users to explore their ancestry, genealogy, and inherited traits. Additionally, the company markets its services to researchers and scientists, offering categorized and searchable genetic data. With a focus on consumer and research services, 23andMe is positioned within the rapidly growing biotech and healthcare sectors, contributing to the understanding of genetics and its implications for health.